1 Top Healthcare Stock to Buy Low Today

Cardiol Therapeutics Inc. (TSX:CRDL) is an exciting healthcare stock that aims to make strides in the application of CBD going forward.

| More on:
Test tubes

Image source: Getty Images

Cardiol Therapeutics (TSX:CRDL) is an Oakville-based clinical-stage biotechnology company that is focused on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). In late 2021, I’d looked at some of the top healthcare stocks that were worth snatching up before the new year. Today, I want to discuss whether Cardiol is worth buying as we prepare to move into the month of February.

This healthcare stock has gained momentum in 2022

Shares of Cardiol Therapeutics have climbed 6.3% week over week as of early afternoon trading on January 31. The stock is up 1.2% so far this year. However, Cardiol stock is still down 25% in the year-over-year period.

Health care is already one of the most explosive sectors that investors can target right now. However, biotechnology is its fastest-growing subsector. In 2021, Grand View Research estimated that the global biotechnology market was valued at US$752 billion in 2020. The market researcher projects that this market will deliver a CAGR of 15% from 2021 through 2028. This should spur investors to get in on this healthcare stock as January comes to an end.

How has this company performed recently?

Investors can expect to see this company’s fourth-quarter and full-year 2021 results in late March. It released its third-quarter 2021 earnings on November 15. Cardiol’s lead product — CardiolRx — is an oral cannabidiol formulation. Cardiol’s total current assets have climbed to $30.9 million at the end of Q3 2021 — up from $14.9 million as of September 31, 2020.

The FDA recently gave Cardiol clearance to move forward with its Phase II multi-centre, randomized controlled trial of CardiolRx among 100 patients with acute myocarditis (AM). This trial will include patients in Europe and the United States.

Acute myocarditis does not have a widely effective and uniform treatment. Cardiol’s leadership has hailed the anti-inflammatory and cardioprotective properties of CBD in models of cardiovascular disease. Of course, this research is still in its very early stages. The utility of CBD as a legitimate medicine is a matter of some debate. Cardiol’s ongoing trials may provide some much-needed clarity on this point.

Myocarditis is a disease that affects roughly 200,000 people in the United States and Canada. The development of a proven new therapy would put Cardiol in a terrific position to fill the void for treatment in the year ahead.

Should you buy Cardiol stock today?

Cardiol is on pace for strong revenue growth going forward. This should spur investors to take a hard look at this healthcare stock as we move into February. Moreover, it boats an excellent balance sheet.

This company is projecting multi-million-dollar revenues by 2022. Shares of this healthcare stock are trading in favourable value territory compared to its industry peers. Investors should remember that this clinical-stage company offers significant risk. That said, it has nice potential, as it seeks to make a breakthrough treating a disease that thus far has puzzled the medical community. Moreover, it will provide a big test for the viability of CBD in this sphere.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

growing plant shoots on stacked coins

Got $5,000? 3 Stocks to Hold for the Next 20 Years

Given their high-growth potential and solid growth initiatives, these three stocks are excellent additions to your long-term portfolio.

Read more »

money cash dividends

TFSA Passive Income: Make $455/Month Tax Free for Life

Canadian investors can churn out big passive income in their TFSA with stocks like Freehold Royalties Ltd. (TSX:FRU) and others…

Read more »

Natural gas
Energy Stocks

Canadian Natural Resources Stock (TSX:CNQ): Profiting From Natural Gas Strength

Soaring cash flows and dividends have come to characterize Canadian Natural Resources stock as well as other natural gas stocks.

Read more »

Question marks in a pile

Uranium Stocks: Ready for a Breakout?

Uranium mining stocks like Cameco Corporation (TSX:CCO)(NYSE:CCJ) could be ready for a breakout.

Read more »

grow dividends
Dividend Stocks

1 Cheap Stock to Turn a $20,000 TFSA Into $267,000

If you're looking to boost your TFSA, you need a cheap stock that you can hold for decades. And I…

Read more »

Profit dial turned up to maximum

This Little-Known TSX Stock Has Huge Potential

From new technologies to unglamorous but promising service businesses, there are plenty of potentially explosive, little-known stocks trading on Canadian…

Read more »

Canadian Dollars
Stocks for Beginners

How a $10,000 TFSA or RRSP Investment Can Become $193,000

Are you looking to build wealth for retirement? Here's one way that turned a $10,000 TFSA or RRSP investment into…

Read more »

edit Person using calculator next to charts and graphs
Dividend Stocks

2 of the Best Monthly Passive-Income Stocks to Buy in Canada Right Now

Here are two of the best Canadian monthly passive income stocks you can consider buying right now to hold for…

Read more »